Darexaban clinical trials
Also written YM150.
How each study uses darexaban is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
25 studies that test it; most in 2009 (11)
| Year | Studies |
|---|---|
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 11 |
| 2010 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Factor Xa inhibitors source
Studies
Open first, then newest update. How each study uses darexaban is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement SurgeryCompletedPhase 2/3Astellas Pharma Europe B.V.NCT00902928Written as YM150
- Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary SyndromesCompletedPhase 2Astellas Pharma Europe B.V.NCT00994292Written as YM150
- To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)CompletedPhase 1Astellas Pharma IncNCT01405989Written as darexaban
- A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male SubjectsCompletedPhase 1Astellas Pharma Europe B.V.NCT01657981Written as YM150
- A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the BodyCompletedPhase 1Astellas Pharma Europe B.V.NCT01655056Written as YM150
- To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their EffectsCompletedPhase 1Astellas Pharma IncNCT01409603Written as darexaban
- To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)CompletedPhase 1Astellas Pharma IncNCT01406002Written as darexaban
- A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement SurgeryCompletedPhase 2Astellas Pharma IncNCT00595426Written as YM150
- To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their EffectsCompletedPhase 1Astellas Pharma IncNCT01409616Written as darexaban
- Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)CompletedPhase 2Astellas Pharma IncNCT00353678Written as YM150
- A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly SubjectsCompletedPhase 1Astellas Pharma IncNCT01514825Written as YM150
- A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy SubjectsCompletedPhase 1Astellas Pharma IncNCT01514812Written as YM150
- Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee ReplacementCompletedPhase 2Astellas Pharma IncNCT00408239Written as YM150
- Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial FibrillationCompletedPhase 2Astellas Pharma IncNCT00448214Written as YM150
- To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their EffectsCompletedPhase 1Astellas Pharma IncNCT01424332Written as Darexaban
- A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial FibrillationCompletedPhase 2Astellas Pharma IncNCT00938730Written as YM150
- Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous ThromboembolismCompletedPhase 3Astellas Pharma IncNCT00937820Written as YM150
- A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal SurgeryCompletedPhase 3Astellas Pharma IncNCT00942435Written as YM150
- YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical IllnessCompletedPhase 3Astellas Pharma IncNCT01028950Written as YM150
- Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower ExtremitiesCompletedPhase 3Astellas Pharma IncNCT00937911Written as YM150
Codes
What other systems call darexaban · ClinicalTrials.gg INT005986
- MeSH (NLM) C569750darexabanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) KF322K101SDAREXABANConfirmed FDA, NLM, Wikidata
- Wikidata Q5222570darexabanConfirmed FDA, NLM, Wikidata
- DrugBank DB12289One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C569750 | darexaban | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | KF322K101S | DAREXABAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5222570 | darexaban | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB12289 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.